高级检索
当前位置: 首页 > 详情页

GRHL3 drives radiotherapy resistance and blocks the anti-tumor response of NK and CD4+ T cells in lung squamous cell carcinoma via RNF2

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai 054000 Hebei, PR China [2]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China [3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China [4]Department of Surgical Oncology, Handan Central Hospital, Handan 056000 Hebei, PR China [5]School of Clinical Sciences, Hebei Medical University, Shijiazhuang 050000 Hebei, PR China
出处:
ISSN:

关键词: GRHL3 RNF2 Radiotherapy Immunotherapy Lung squamous cell carcinoma

摘要:
Grainyhead-like protein 3 homolog (GRHL3) has been identified as a top transcription factor associated with keratinization in lung squamous cell carcinoma (LUSC). We designed this study to elucidate the function of GRHL3 in radioresistance in LUSC and the mechanism involved. Transcriptome differences between radioresistant and parental cells were analyzed to identify the hub transcription factor. GRHL3 expression was overexpressed in radioresistant cells relative to parental cells, and the knockdown of GRHL3 conferred sensitivity to radioresistant LUSC cells, induced DNA damage, inhibited cell survival, and reduced tumor load in mice. GRHL3 promoted ring finger protein 2 (RNF2) transcription by binding to the RNF2 promoter. GRHL3 induced a radioresistant phenotype in parental cells and led to compromised anti-tumor immune responses of CD4+ T cells and NK cells. The GRHL3-promoted tumor progression was reversed by the knockdown of RNF2. The DNA methylation of GRHL3 was reduced in radioresistant cells. All in all, as GRHL3, helps LUSC cells escape from the immune surveillance and mediates radioresistance, it might be an attractive target for therapy-resistant LUSC.Copyright © 2025. Published by Elsevier Inc.

基金:
语种:
WOS:
PubmedID:
中科院分区:
出版当年[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学
JCR分区:
出版当年[2024]版:
Q1 PHARMACOLOGY & PHARMACY
最新[2024]版:
Q1 PHARMACOLOGY & PHARMACY

影响因子: 最新[2024版] 最新五年平均 出版当年[2025版] 出版当年五年平均 出版前一年[2024版]

第一作者:
第一作者机构: [1]Department of Thoracic Surgery, Xingtai People’s Hospital, Xingtai 054000 Hebei, PR China
共同第一作者:
通讯作者:
通讯机构: [3]Department of Radiotherapy, The Fourth Hospital of Hebei Medical University, Shijiazhuang 050000 Hebei, PR China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42325 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号